메뉴 건너뛰기




Volumn 93, Issue 4, 2004, Pages 453-455

Incidence and time course of thrombocytopenia with Abciximab and Eptifibatide in patients undergoing percutaneous coronary intervention

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; EPTIFIBATIDE;

EID: 1242270514     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.041     Document Type: Article
Times cited : (10)

References (12)
  • 1
    • 0031055038 scopus 로고    scopus 로고
    • Acute profound thrombocytopenia after c7E Fab (abciximab) therapy
    • Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after c7E Fab (abciximab) therapy. Circulation. 95:1997;809-813.
    • (1997) Circulation , vol.95 , pp. 809-813
    • Berkowitz, S.D.1    Harrington, R.A.2    Rund, M.M.3    Tcheng, J.E.4
  • 2
    • 0027240597 scopus 로고
    • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
    • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
    • (1993) N Engl J Med , vol.329 , pp. 673-682
  • 3
    • 0023864355 scopus 로고
    • Thrombolysis in Myocardial Infarction (TIMI) trial - Phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
    • Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) trial - phase I. hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.
    • (1988) J Am Coll Cardiol , vol.11 , pp. 1-11
    • Rao, A.K.1    Pratt, C.2    Berke, A.3    Jaffe, A.4    Ockene, I.5    Schreiber, T.L.6    Bell, W.R.7    Knatterud, G.8    Robertson, T.L.9    Terrin, M.L.10
  • 4
    • 0033869435 scopus 로고    scopus 로고
    • Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis
    • Dasgupta H., Blankenship J.C., Wood G.C., Frey C.M., Demko S.L., Menapace F.J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors a pooled analysis . Am Heart J. 140:2000;206-211.
    • (2000) Am Heart J , vol.140 , pp. 206-211
    • Dasgupta, H.1    Blankenship, J.C.2    Wood, G.C.3    Frey, C.M.4    Demko, S.L.5    Menapace, F.J.6
  • 5
    • 2242477091 scopus 로고
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
    • (1994) N Engl J Med , vol.330 , pp. 956-961
  • 6
    • 1842369101 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
    • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
    • (1997) N Engl J Med , vol.336 , pp. 1689-1696
  • 7
    • 0030918995 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
    • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
    • (1997) Lancet , vol.349 , pp. 1429-1435
  • 8
    • 0032508297 scopus 로고    scopus 로고
    • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade
    • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. Lancet. 352:1998;87-92.
    • (1998) Lancet , vol.352 , pp. 87-92
  • 9
    • 0035927988 scopus 로고    scopus 로고
    • Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
    • Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.-J., Stone G.W., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 244:2001;1888-1894.
    • (2001) N Engl J Med , vol.244 , pp. 1888-1894
    • Topol, E.J.1    Moliterno, D.J.2    Herrmann, H.C.3    Powers, E.R.4    Grines, C.L.5    Cohen, D.J.6    Cohen, E.A.7    Bertrand, M.8    Neumann, F.-J.9    Stone, G.W.10
  • 10
    • 0035897893 scopus 로고    scopus 로고
    • Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
    • Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation the GUSTO IV-ACS randomised trial . Lancet. 357:2001;1915-1924.
    • (2001) Lancet , vol.357 , pp. 1915-1924
  • 11
    • 0035897888 scopus 로고    scopus 로고
    • Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
    • Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition the GUSTO V randomised trial . Lancet. 357:2001;1905-1914.
    • (2001) Lancet , vol.357 , pp. 1905-1914


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.